AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

An analyst has a suggestion for AstraZeneca PLC (NASDAQ:AZN) shareholders concerned about negative publicity about the company's Covid vaccine: relax.

Analysts: Focus on AstraZeneca's Positives, Not Vaccine Issue

After more than a dozen countries paused the use of AstraZeneca's coronavirus vaccine due to concerns about blood clots, the European Medicines Agency concluded on Thursday that the vaccine doesn't increase the risk of clotting. The World Health Organization, too, recommended that countries continue to administer AstraZeneca's vaccine, since the benefits of the shot "outweigh its risks."

The US hasn't authorized AstraZeneca's vaccine for 2 main reasons. That could change in April.

The vaccine is not associated with an increase in the overall risk of blood clots, the European Medicines Agency found.

AstraZeneca's COVID vaccine is safe, says European regulator after blood clot concerns

The European Medicines Agency said the benefits of the Covid-19 vaccine outweighed the possible risks, in a press briefing on Thursday.

EU Regulator Says AstraZeneca Vaccine Is ‘Safe and Effective' After Blood Clot Investigation

The U.S. is planning to send 4 million doses of the AstraZeneca COVID-19 vaccine to Mexico and Canada, the White House said Thursday. White House press secretary Jen Psaki described the arrangements as loans, with 2.5 million doses going to Mexico and 1.5 million doses for Canada.

U.S. plans to send AstraZeneca vaccine doses to Canada, Mexico: White House

The agency said it was unable to decisively rule out a link between some extremely rare blood clotting events and the vaccine but felt the benefits of getting vaccinated outweighed the risks.

EU Agency OKs AstraZeneca Vaccine Ruling Out Broad Link To Blood Clotting

Finally, the much-awaited safety review of blood clot reports is now complete and the European Medicines Agency (EMA) concluded that AstraZeneca Plc's (NASDAQ: AZN) COVID vaccine is "safe and effective". What Happened: The highly anticipated opinion comes at a time when the European Union is witnessing a vaccine shortage, and the bloc is suffering yet another surge in COVID-19 infection cases.

EMA 'Firmly Convinced' With Benefits Of AstraZeneca Vaccine Exceeding Risks: Report

Europe's regulator has concluded that the AstraZeneca COVID-19 vaccine is "safe and effective," following its investigation into reports of blood clots in people that had received the shot.

EU regulator says AstraZeneca vaccine is safe and effective after blood clot investigation.

AstraZeneca and Oxford University's COVID-19 vaccine is safe and its benefits clearly outweigh its risks, the European regulator said Thursday. The European Medicines Agency (EMA) said in a press briefing that AstraZeneca's vaccine was not associated with higher levels of blood clots, following a investigation into reports that people who had received the vaccine developed clots.

AstraZeneca's vaccine is safe, Europe's regulator said following an investigation into potential side effects. 18 countries could now lift their suspensions of the shot.

AstraZeneca stock remained under pressure Thursday as European medical regulators met to discuss the company's Covid-19 vaccine amid increasing concerns of blood clots. The post AstraZeneca Under Pressure As Its Covid Vaccine Faces Another Challenge appeared first on Investor's Business Daily.

AstraZeneca Under Pressure As Its Covid Vaccine Faces Another Challenge

The EMA said Thursday that the benefits of the vaccine outweighed the risks.

European regulator greenlights AstraZeneca coronavirus vaccine after reports of blood clots

The European Commission will send a letter to AstraZeneca as the first step of efforts to resolve a dispute with the company over its supplies of COVID-19 vaccines to the bloc, Reuters reports. What Happened: Yesterday, European Commission's President Ursula von der Leyen threatened to stop vaccine exports to safeguard scarce doses unless the U.K. starts shipping shots to the bloc.

AstraZeneca Set To Get Letter From EU As First Step Of Legal Action For Delayed Deliveries: Reuters

Los Angeles, California--(Newsfile Corp. - March 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC (NASDAQ: AZN) ("AstraZeneca" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the ''Class Period''),...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Goldman Sachs analysts said Europe's strong growth rebound wouldn't be derailed, whatever the outcome from the EU's drug regulator on Thursday.

Why the AstraZeneca Vaccine Suspension Won't Derail Europe's Growth Rebound

AstraZeneca PLC (LON:AZN) is set to hear the EU regulator's decision on the COVID-19 vaccine developed with Oxford University later today. Experts from the European Medicines Agency (EMA) are discussing whether to keep rolling out the jab in the bloc after there were cases of blood clots in people who had received it.

AstraZeneca to hear from EU regulator on COVID-19 vaccine today

Europe's medicines regulator is set to report on the safety of the AstraZeneca COVID-19 vaccine on Thursday, after several countries suspended its use.

Why Goldman says the AstraZeneca vaccine suspension isn't a game changer for growth

Oxford University and drug giant AstraZeneca have found themselves at the heart of European political theatre over the past few weeks. The groups' COVID-19 vaccine has been suspended in more than a dozen European countries after a small number of blood clots, including with "unusual features" such as low platelets, were reported in a few people immunized with AstraZeneca's shot. Vaccine regulators and the World Health Organization (WHO) have said the vaccine is safe — but after Denmark suspended the shot on March 11, country after country followed, saying they would wait on the results of an investigation from the European Medicines Agency (EMA), which is expected to conclude later on Thursday.

The future of AstraZeneca's vaccine rollout hinges on 2 crucial decisions, after a month of suspensions and dose shortages

The country halted the use of AstraZeneca's vaccine after more than a dozen countries in Europe suspended the vaccine due to blood clot concerns.

Indonesia will restart AstraZeneca vaccines when regulators give the go ahead, health minister says

New York, New York--(Newsfile Corp. - March 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

ROSEN, A RESPECTED LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important March 29 Deadline in Securities Class Action - AZN

"This will require major damage control," Dr. Carlos del Rio, a professor of medicine at the Emory University School of Medicine, told CNBC.

U.S. health experts try to ease Covid vaccine fears as AstraZeneca's shot faces review in Europe

Many European countries ignored the WHO and EU medicines regulator and suspended the shot over fears it causes blood clots.

E.U. Chief Blames AstraZeneca For Floundering Vaccination Drive While Member States Refuse To Use It Against Expert Advice

"Vaccination against COVID-19 will not reduce illness or deaths from other causes," the World Health Organization said.

WHO urges countries to keep using AstraZeneca vaccine as ‘benefits outweigh risks'

Los Angeles, California--(Newsfile Corp. - March 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC (NASDAQ: AZN) ("AstraZeneca" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the ''Class...

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The latest guidance from the global public health body comes after a raft of European countries announced that they would suspend use of the shot.

WHO recommends AstraZeneca vaccinations continue, says benefits still outweigh risks

At least two European Union countries plan to start using AstraZeneca's coronavirus vaccine again if regulators give the green light this week. France and Italy agreed to “promptly” resume their rollout of the British drugmaker's shot if the European Medicines Agency formally confirms that it's safe to use amid concerns about people who received it.

News for AstraZeneca Stock (AZN)